Genetics of glioblastoma: a window into its imaging and histopathologic variability.

Glioblastoma is a highly malignant brain tumor that relentlessly defies therapy. Efforts over the past decade have begun to tease out the biochemical details that lead to its aggressive behavior and poor prognosis. There is hope that this new understanding will lead to improved treatment strategies for patients with glioblastoma, in the form of targeted, molecularly based therapies that are individualized to specific changes in individual tumors. However, these new therapies have the potential to fundamentally alter the biologic behavior of glioblastoma and, as a result, its imaging appearance. Knowledge about common genetic alterations and the resultant cellular and tissue changes (ie, induced angiogenesis and abnormal cell survival, proliferation, and invasion) in glioblastomas is important as a basis for understanding imaging findings before treatment. It is equally critical that radiologists understand which genetic pathway is targeted by each specific therapeutic agent or class of agents in order to accurately interpret changes in the imaging appearances of treated tumors.

[1]  H. Shimizu,et al.  Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. , 2000, AJNR. American journal of neuroradiology.

[2]  M. Frosch,et al.  Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[4]  G. Riggins,et al.  A survey of glioblastoma genomic amplifications and deletions , 2009, Journal of Neuro-Oncology.

[5]  Catherine Dumur,et al.  Microarray Analysis of MRI-defined Tissue Samples in Glioblastoma Reveals Differences in Regional Expression of Therapeutic Targets , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[6]  A. Harris,et al.  Mechanisms of resistance to antiangiogenesis therapy. , 2010, European journal of cancer.

[7]  D. Louis The p53 Gene and Protein in Human Brain Tumors , 1994, Journal of neuropathology and experimental neurology.

[8]  M. Chamberlain Radiographic patterns of relapse in glioblastoma , 2010, Journal of Neuro-Oncology.

[9]  P. Wen,et al.  A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.

[10]  Erwin G. Van Meir,et al.  Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma , 2010, CA: a cancer journal for clinicians.

[11]  D. Leavesley,et al.  Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen , 1992, The Journal of cell biology.

[12]  I. Date,et al.  Angiogenesis and invasion in glioma , 2011, Brain Tumor Pathology.

[13]  P. Wen,et al.  Bevacizumab for recurrent malignant gliomas , 2008, Neurology.

[14]  Dushyant V. Sahani,et al.  Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.

[15]  Hiroyuki Kabasawa,et al.  Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas. , 2005, Surgical neurology.

[16]  Giuseppe Sciumè,et al.  Chemokines and glioma: Invasion and more , 2010, Journal of Neuroimmunology.

[17]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Louis,et al.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.

[19]  P. Wen,et al.  Antiangiogenic strategies for treatment of malignant gliomas , 2009, Neurotherapeutics.

[20]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[21]  G. Gores,et al.  Life and death by death receptors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[23]  Tracy T Batchelor,et al.  Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. , 2010, Neuro-oncology.

[24]  W. Broaddus,et al.  The Role of Matrix Metalloproteinase Genes in Glioma Invasion: Co-dependent and Interactive Proteolysis , 2001, Journal of Neuro-Oncology.

[25]  W. A. Galloway,et al.  Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. , 1998, British journal of clinical pharmacology.

[26]  Ru-Fang Yeh,et al.  Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. , 2010, Radiology.

[27]  G. Reifenberger,et al.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.

[28]  Yiping Deng,et al.  Expression of Matrix Metalloproteinase-26 promotes human glioma U251 cell invasion in vitro and in vivo. , 2009, Oncology reports.

[29]  B. Aggarwal Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[30]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[31]  M. Weller,et al.  Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. , 2001, Cancer research.

[32]  E. Jouanneau ANGIOGENESIS AND GLIOMAS: CURRENT ISSUES AND DEVELOPMENT OF SURROGATE MARKERS , 2008, Neurosurgery.

[33]  K. Aldape,et al.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.

[34]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[35]  Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics , 2010, Molecular Cancer.

[36]  P. Meltzer,et al.  Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. , 1994, Cancer research.

[37]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[38]  C. Dullin,et al.  Tumor localization of an anti-TGF-β antibody and its effects on gliomas. , 2010, International journal of oncology.

[39]  Paul S Mischel,et al.  MR imaging correlates of survival in patients with high-grade gliomas. , 2005, AJNR. American journal of neuroradiology.

[40]  M. Martínez-Bisbal,et al.  Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[41]  Christopher Logothetis,et al.  Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. , 2010, Cancer treatment reviews.

[42]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Mahlon D. Johnson,et al.  Vascular gene expression patterns are conserved in primary and metastatic brain tumors , 2010, Journal of Neuro-Oncology.

[44]  Matthew S. Brown,et al.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.

[45]  G. Fuller,et al.  Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas , 2004, Laboratory Investigation.

[46]  Andrew D Norden,et al.  Therapeutic strategies for inhibiting invasion in glioblastoma , 2009, Expert review of neurotherapeutics.

[47]  Inna N Lavrik,et al.  Caspases: pharmacological manipulation of cell death. , 2005, The Journal of clinical investigation.

[48]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[50]  T. Mikkelsen,et al.  Targeting integrins in malignant glioma , 2010, Targeted Oncology.

[51]  M. Essig,et al.  Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes , 2010, Acta Neuropathologica.

[52]  Paul S Mischel,et al.  Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. , 2008, Radiology.

[53]  D. Ashley,et al.  Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells , 2001, Oncogene.

[54]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[55]  E. Holland,et al.  Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. , 2005, Cancer research.

[56]  A. Wesołowska,et al.  Microglia-derived TGF-β as an important regulator of glioblastoma invasion—an inhibition of TGF-β-dependent effects by shRNA against human TGF-β type II receptor , 2008, Oncogene.

[57]  R. Mahfouz,et al.  Understanding the biology of angiogenesis: review of the most important molecular mechanisms. , 2007, Blood cells, molecules & diseases.

[58]  A. Jackson,et al.  Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? , 2006, AJNR. American journal of neuroradiology.